Dietary fat and heart failure: Moving from lipotoxicity to lipoprotection

Circulation Research

Volumn 110, Issue 5, 2012, Pages 764-776

  Stanley, William C ^a   Dabkowski, Erinne R ^a   Ribeiro, Rogerio F ^a   O'Connell, Kelly A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

heart failure; lipids; mitochondria; nutrition; polyunsaturated fatty acids

Indexed keywords

CHOLESTEROL; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LIPID; MONOUNSATURATED FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID;

CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; FAT INTAKE; GENE EXPRESSION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN RELEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID STORAGE; LIPOTOXICITY; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HEART FAILURE; LIPID METABOLISM; LIPIDS; MICE; RATS;

EID: 84857882542     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.253104     Document Type: Review

References (156)

1. Rennison JH, McElfresh TA, Okere IC, Patel HV, Foster AB, Patel KK, Stoll MS, Minkler PE, Fujioka H, Hoit BD, Young ME, Hoppel CL, Chandler MP. Enhanced acyl-CoA dehydrogenase activity is associated with improved mitochondrial and contractile function in heart failure. Cardiovasc Res. 2008;79:331-340. (Pubitemid 351951606)
2. Okere IC, Chess DJ, McElfresh TA, Johnson J, Rennison J, Ernsberger P, Hoit BD, Chandler MP, Stanley WC. High-fat diet prevents cardiac hypertrophy and improves contractile function in the hypertensive Dahl salt-sensitive rat. Clin Exp Pharmacol Physiol. 2005;32:825-831. (Pubitemid 43906525)
3. Okere IC, Young ME, McElfresh TA, Chess DJ, Sharov VG, Sabbah HN, Hoit BD, Ernsberger P, Chandler MP, Stanley WC. Lowcarbohydrate/ high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension. 2006;48: 1116-1123. (Pubitemid 44772716)
4. Sharma N, Okere IC, Duda MK, Johnson J, Yuan CL, Chandler MP, Ernsberger P, Hoit BD, Stanley WC. High fructose diet increases mortality in hypertensive rats compared to a complex carbohydrate or high fat diet. Am J Hypertens. 2007;20:403-409. (Pubitemid 46441753)
5. Sharma N, Okere IC, Barrows BR, Lei B, Duda MK, Yuan CL, Previs SF, Sharov VG, Azimzadeh AM, Ernsberger P, Hoit BD, Sabbah H, Stanley WC. High-sugar diets increase cardiac dysfunction and mortality in hypertension compared to low-carbohydrate or high-starch diets. J Hypertens. 2008;26:1402-1410.
6. Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC. Low-carbohydrate/high-fat diet attenuates pressure overload-induced ventricular remodeling and dysfunction. J Card Fail. 2008;14:327-335. (Pubitemid 351636236)
7. Galvao TF, Brown BH, Hecker PA, O'Connell KA, O'Shea KM, Sabbah HN, Rastogi S, Daneault C, Des Rosiers C, Stanley WC. High intake of saturated fat, but not polyunsaturated fat, improves survival in heart failure despite persistent mitochondrial defects. Cardiovasc Res. 2011;93:24-32.
8. Chicco AJ, Sparagna GC, McCune SA, Johnson CA, Murphy RC, Bolden DA, Rees ML, Gardner RT, Moore RL. Linoleate-rich high-fat diet decreases mortality in hypertensive heart failure rats compared with lard and low-fat diets. Hypertension. 2008;52:549-555.
9. Christopher BA, Huang HM, Berthiaume JM, McElfresh TA, Chen X, Croniger CM, Muzic RF Jr., Chandler MP. Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function. Am J Physiol Heart Circ Physiol. 2010; 299:H1917-H1927.
10. Berthiaume JM, Bray MS, McElfresh TA, Chen X, Azam S, Young ME, Hoit BD, Chandler MP. The myocardial contractile response to physiological stress improves with high saturated fat feeding in heart failure. Am J Physiol Heart Circ Physiol. 2010;299:H410-H421.
11. Halton TL, Willett WC, Liu S, Manson JE, Albert CM, Rexrode K, Hu FB. Low-carbohydrate-diet score and the risk of coronary heart disease in women. N Engl J Med. 2006;355:1991-2002. (Pubitemid 44708018)
12. Hu FB. Diet and cardiovascular disease prevention the need for a paradigm shift. J Am Coll Cardiol. 2007;50:22-24.
13. Mozaffarian D, Appel LJ, Van HL. Components of a cardioprotective diet: new insights. Circulation. 2011;123:2870-2891.
14. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16: e1-e194.
15. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2000;114:82-96.
16. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-2442.
17. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002;288:2569-2578. (Pubitemid 35386892)
18. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:655-666. (Pubitemid 43209067)
19. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54:585-594.
20. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047-2067.
21. Beulens JW, de Bruijne LM, Stolk RP, Peeters PH, Bots ML, Grobbee DE, van der Schouw YT. High dietary glycemic load and glycemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study. J Am Coll Cardiol. 2007;50: 14-21. (Pubitemid 46963529)
22. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011;364:2392-2404.
23. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88:389-419. (Pubitemid 351520084)
24. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925-1932.
25. Levitan EB, Wolk A, Mittleman MA. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years. Am J Cardiol. 2009;104:1416-1420.
26. Levitan EB, Wolk A, Mittleman MA. Consistency with the DASH diet and incidence of heart failure. Arch Intern Med. 2009;169:851-857.
27. Lemon SC, Olendzki B, Magner R, Li W, Culver AL, Ockene I, Goldberg RJ. The dietary quality of persons with heart failure in NHANES 1999-2006. J Gen Intern Med. 2010;25:135-140.
28. Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007;101:335-347. (Pubitemid 47267702)
29. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285: 17271-17276.
30. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313. (Pubitemid 34815352)
31. Okere IC, Chandler MP, McElfresh TA, Rennison JH, Sharov V, Sabbah HN, Tserng KY, Hoit BD, Ernsberger P, Young ME, Stanley WC. Differential effects of saturated and unsaturated fatty acid diets on cardiomyocyte apoptosis, adipose distribution, and serum leptin. Am J Physiol Heart Circ Physiol. 2006;291:H38-H44.
32. Rennison JH, McElfresh TA, Okere IC, Vazquez EJ, Patel HV, Foster AB, Patel KK, Chen Q, Hoit BD, Tserng KY, Hassan MO, Hoppel CL, Chandler MP. High-fat diet postinfarction enhances mitochondrial function and does not exacerbate left ventricular dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1498-H1506. (Pubitemid 46377138)
33. Aguila MB, Mandarim-de-Lacerda CA. Heart and blood pressure adaptations in Wistar rats fed with different high-fat diets for 18 months. Nutrition. 2003;19:347-352. (Pubitemid 36390130)
34. Okere IC, Chandler MP, McElfresh TA, Rennison JH, Kung TA, Hoit BD, Ernsberger P, Young ME, Stanley WC. Carnitine palmitoyl transferase-I inhibition is not associated with cardiac hypertrophy in rats fed a high-fat diet. Clin Exp Pharmacol Physiol. 2007;34:113-119. (Pubitemid 46069595)
35. Fang CX, Dong F, Thomas DP, Ma H, He L, Ren J. Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Am J Physiol Heart Circ Physiol. 2008;295:H1206-H1215.
36. Wilson CR, Tran MK, Salazar KL, Young ME, Taegtmeyer H. Western diet, but not high fat diet, causes derangements of fatty acid metabolism and contractile dysfunction in the heart of Wistar rats. Biochem J. 2007;406:457-467. (Pubitemid 47425452)
37. Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, Tserng KY, Hoit BD, Stanley WC, Chandler MP. Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol. 2006;290:H1899-H1904.
38. Chess DJ, Lei B, Hoit BD, Azimzadeh AM, Stanley WC. Effects of a high saturated fat diet on cardiac hypertrophy and dysfunction in response to pressure overload. J Card Fail. 2008;14:82-88.
39. Chess DJ, Khairallah RJ, O'Shea KM, Xu W, Stanley WC. A high-fat diet increases adiposity but maintains mitochondrial oxidative enzymes without affecting development of heart failure with pressure overload. Am J Physiol Heart Circ Physiol. 2009;297:H1585-H1593.
40. Fitzgerald SM, Henegar JR, Brands MW, Henegar LK, Hall JE. Cardiovascular and renal responses to a high-fat diet in Osborne-Mendel rats. Am J Physiol Regul Integr Comp Physiol. 2001;281:R547-R552.
41. Park SY, Cho YR, Kim HJ, Higashimori T, Danton C, Lee MK, Dey A, Rothermel B, Kim YB, Kalinowski A, Russell KS, Kim JK. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes. 2005;54: 3530-3540. (Pubitemid 43334346)
42. Ouwens DM, Boer C, Fodor M, de GP, Heine RJ, Maassen JA, Diamant M. Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia. 2005;48: 1229-1237. (Pubitemid 40909661)
43. Pladevall M, Williams K, Guyer H, Sadurni J, Falces C, Ribes A, Pare C, Brotons C, Gabriel R, Serrano-Rios M, Haffner S. The association between leptin and left ventricular hypertrophy: a population-based cross-sectional study. J Hypertens. 2003;21:1467-1473. (Pubitemid 36994124)
44. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14:281-287. (Pubitemid 36688207)
45. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001;107:813-822. (Pubitemid 32274034)
46. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000;97:1784-1789. (Pubitemid 30118520)
47. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007;101:759-767. (Pubitemid 350287190)
48. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res. 2005;96:225-233. (Pubitemid 40209370)
49. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109:121-130. (Pubitemid 34052548)
50. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003;100:1226-1231. (Pubitemid 36183984)
51. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest. 2003;111: 419-426. (Pubitemid 36182219)
52. Klotz S, Hay I, Zhang G, Maurer M, Wang J, Burkhoff D. Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension. 2006;47:901-911. (Pubitemid 44297562)
53. Raher MJ, Thibault HB, Buys ES, Kuruppu D, Shimizu N, Brownell AL, Blake SL, Rieusset J, Kaneki M, Derumeaux G, Picard MH, Bloch KD, Scherrer-Crosbie M. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am J Physiol Heart Circ Physiol. 2008;295: H2495-H2502.
54. Hajri T, Ibrahimi A, Coburn CT, Knapp FF Jr., Kurtz T, Pravenec M, Abumrad NA. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem. 2001;276: 23661-23666.
55. Fiaccavento R, Carotenuto F, Minieri M, Masuelli L, Vecchini A, Bei R, Modesti A, Binaglia L, Fusco A, Bertoli A, Forte G, Carosella L, Di NP. Alpha-linolenic acid-enriched diet prevents myocardial damage and expands longevity in cardiomyopathic hamsters. Am J Pathol. 2006;169: 1913-1924. (Pubitemid 351181954)
56. Chess DJ, Stanley WC. Role of diet and fuel overabundance in the development and progression of heart failure. Cardiovasc Res. 2008;79: 269-278. (Pubitemid 351951607)
57. Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90:23-46.
58. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, III, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005;294:2455-2464. (Pubitemid 41627923)
59. Schaefer EJ, Gleason JA, Dansinger ML. The effects of low-fat, highcarbohydrate diets on plasma lipoproteins, weight loss, and heart disease risk reduction. Curr Atheroscler Rep. 2005;7:421-427. (Pubitemid 43033767)
60. Gardner CD, Kiazand A, Alhassan S, Kim S, Stafford RS, Balise RR, Kraemer HC, King AC. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA. 2007;297:969-977. (Pubitemid 46376751)
61. Jenkins DJ, Wong JM, Kendall CW, Esfahani A, Ng VW, Leong TC, Faulkner DA, Vidgen E, Greaves KA, Paul G, Singer W. The effect of a plant-based low-carbohydrate ("Eco-Atkins") diet on body weight and blood lipid concentrations in hyperlipidemic subjects. Arch Intern Med. 2009;169:1046-1054.
62. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a lowcarbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359: 229-241. (Pubitemid 352008438)
63. Chess DJ, Lei B, Hoit BD, Azimzadeh AM, Stanley WC. Deleterious effects of sugar and protective effects of starch on cardiac remodeling, contractile dysfunction, and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol. 2007;293:H1853-H1860. (Pubitemid 47367235)
64. Chess DJ, Xu W, Khairallah R, O'Shea KM, Kop WJ, Azimzadeh AM, Stanley WC. The antioxidant tempol attenuates pressure overloadinduced cardiac hypertrophy and contractile dysfunction in mice fed a high-fructose diet. Am J Physiol Heart Circ Physiol. 2008;295: H2223-H2230.
65. Shigematsu Y, Hara Y, Ohtsuka T, Ohgimoto A, Inoue K, Higaki J. Relation of genetic predisposition and insulin resistance to left ventricular hypertrophy in hypertension. Am J Hypertens. 2005;18:457-463.
66. Karason K, Sjostrom L, Wallentin I, Peltonen M. Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. Eur Heart J. 2003;24:1500-1505. (Pubitemid 37010580)
67. Stiefel P, Miranda ML, Rodriguez-Puras MJ, Garcia-Morillo S, Carneado J, Pamies E, Villar J. Glucose effectiveness is strongly related to left ventricular mass in subjects with stage I hypertension or highnormal blood pressure. Am J Hypertens. 2004;17:146-153. (Pubitemid 38125132)
68. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, Wilson PW, Vasan RS. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003;107: 448-454. (Pubitemid 36158048)
69. Ilercil A, Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Howard BV. Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study. Diabetes. 2002;51:1543-1547. (Pubitemid 34826623)
70. Sharma N, Okere IC, Duda MK, Chess DJ, O'Shea KM, Stanley WC. Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy. Cardiovasc Res. 2007;73:257-268. (Pubitemid 44937701)
71. Taegtmeyer H, Stanley WC. Too much or not enough of a good thing? Cardiac glucolipotoxicity versus lipoprotection. J Mol Cell Cardiol. 2011;50:2-5.
72. Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, Rosner BA, Hennekens CH, Willett WC. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997;337:1491-1499. (Pubitemid 27495774)
73. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010;91:535-546.
74. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.
75. Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008;87: 1981S-1990S. (Pubitemid 351872679)
76. Brouwer IA, Wanders AJ, Katan MB. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans-a quantitative review. PLoS One. 2010;5:e9434.
77. Keys A, Parlin RW. Serum cholesterol response to changes in dietary lipids. Am J Clin Nutr. 1966;19:175-181.
78. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr. 1965;17: 281-295.
79. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146-1155. (Pubitemid 44858429)
80. Mensink RP. Dietary fatty acids and cardiovascular health-an ongoing controversy. Ann Nutr Metab. 2011;58:66-67.
81. Nakae I, Mitsunami K, Yoshino T, Omura T, Tsutamoto T, Matsumoto T, Morikawa S, Inubushi T, Horie M. Clinical features of myocardial triglyceride in different types of cardiomyopathy assessed by proton magnetic resonance spectroscopy: comparison with myocardial creatine. J Card Fail. 2010;16:812-822.
82. McGavock J, Szczepaniak LS, Ayers CR, Abdullah SM, See R, Gore MO, Drazner MH, de Lemos JA, McGuire DK. The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial. Diab Vasc Dis Res. 2011 (in press; PMID:22067724).
83. Wang H, Sreenevasan U, Hu H, Saladino A, Polster BM, Lund LM, Gong DW, Stanley WC, Sztalryd C. Perilipin 5, a lipid dropletassociated protein, provides physical and metabolic linkage to mitochondria. J Lipid Res. 2011;52:2159-2168.
84. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest. 2010;120:3443-3454.
85. Stanley WC, Recchia FA. Lipotoxicity and the development of heart failure: moving from mouse to man. Cell Metab. 2010;12:555-556.
86. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093-1129. (Pubitemid 40894649)
87. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res. 2011;90:202-209.
88. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res. 2004;95:568-578. (Pubitemid 39274371)
89. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res. 2004;61:218-226. (Pubitemid 38091762)
90. Gilde AJ, Van Der Lee KA, Willemsen PH, Chinetti G, Van Der Leij FR, van der Vusse GJ, Staels B, van Bilsen M. Peroxisome proliferatoractivated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003;92:518-524. (Pubitemid 36368664)
91. Barger PM, Kelly DP. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci. 1999; 318:36-42. (Pubitemid 30387273)
92. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest. 2000;105:1723-1730. (Pubitemid 30421753)
93. Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S, D'Agostino C, Hintze TH, Stanley WC, Recchia FA. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res. 2005;66:454-461. (Pubitemid 40725757)
94. Lei B, Lionetti V, Young ME, Chandler MP, D' Agostino C, Kang E, Altarejos M, Matsuo K, Hintze TH, Stanley WC, Recchia FA. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol. 2004;36: 567-576. (Pubitemid 38469947)
95. Morgan EE, Chandler MP, Young ME, McElfresh TA, Kung TA, Rennison JH, Tserng KY, Hoit BD, Stanley WC. Dissociation between gene and protein expression of metabolic enzymes in a rodent model of heart failure. Eur J Heart Fail. 2006;8:687-693. (Pubitemid 44635313)
96. Suzuki G, Khanal S, Rastogi S, Morita H, Mishima T, Anagnostopoulos PV, Nass O, Sharov VG, Tanhehco EJ, Goldstein S, Sabbah HN. Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failure. Cardiovasc Drugs Ther. 2007;21:29-36. (Pubitemid 46594985)
97. Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA. Chronic activation of PPAR{alpha} with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. J Pharmacol Exp Ther. 2007;321:165-171. (Pubitemid 46456959)
98. Brigadeau F, Gele P, Wibaux M, Marquie C, Martin-Nizard F, Torpier G, Fruchart JC, Staels B, Duriez P, Lacroix D. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol. 2007;49:408-415. (Pubitemid 47000316)
99. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, Neubauer S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res. 2003;58:632-637. (Pubitemid 36700421)
100. Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C, Hu TC, Lenhard SC, Costell M, Bernard R, Sarov-Blat L, Steplewski K, Willette RN. PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J Cardiovasc Pharmacol. 2007;50:25-34. (Pubitemid 47220443)
101. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem. 2001;276: 44390-44395.
102. Lockridge JB, Sailors ML, Durgan DJ, Egbejimi O, Jeong WJ, Bray MS, Stanley WC, Young ME. Bioinformatic profiling of the transcriptional response of adult rat cardiomyocytes to distinct fatty acids. J Lipid Res. 2008;49:1395-1408.
103. Osman C, Voelker DR, Langer T. Making heads or tails of phospholipids in mitochondria. J Cell Biol. 2011;192:7-16.
104. O'Shea KM, Khairallah RJ, Sparagna GC, Xu W, Hecker PA, Robillard-Frayne I, Des Rosiers C, Kristian T, Murphy RC, Fiskum G, Stanley WC. Dietary omega-3 fatty acids alter cardiac mitochondrial phospholipid composition and delay Ca2+-induced permeability transition. J Mol Cell Cardiol. 2009;47:819-827.
105. Khairallah RJ, Sparagna GC, Khanna N, O'Shea KM, Hecker PA, Kristian T, Fiskum G, Des Rosiers C, Polster BM, Stanley WC. Dietary supplementation with docosahexaenoic acid, but not eicosapentaenoic acid, dramatically alters cardiac mitochondrial phospholipid fatty acid composition and prevents permeability transition. Biochim Biophys Acta. 2010;1797:1555-1562.
106. Khairallah RJ, O'Shea KM, Brown BH, Khanna N, Des Rosiers C, Stanley WC. Treatment with docosahexaenoic acid, but not eicosapentaenoic acid, delays Ca2+-induced mitochondria permeability transition in normal and hypertrophied myocardium. J Pharmacol Exp Ther. 2010;335:155-162.
107. Rosca M, Minkler P, Hoppel CL. Cardiac mitochondria in heart failure: normal cardiolipin profile and increased threonine phosphorylation of complex IV. Biochim Biophys Acta. 2011;1807:1373-1382.
108. Pepe S, Tsuchiya N, Lakatta EG, Hansford RG. PUFA and aging modulate cardiac mitochondrial membrane lipid composition and Ca2+ activation of PDH. Am J Physiol. 1999;276:H149-H158. (Pubitemid 29065633)
109. Schlame M, Rua D, Greenberg ML. The biosynthesis and functional role of cardiolipin. Prog Lipid Res. 2000;39:257-288. (Pubitemid 30224706)
110. Minkler PE, Hoppel CL. Separation and characterization of cardiolipin molecular species by reverse-phase ion pair high-performance liquid chromatography-mass spectrometry. J Lipid Res. 2010;51:856-865.
111. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol. 2007; 292:C33-C44. (Pubitemid 46115119)
112. Sparagna GC, Lesnefsky EJ. Cardiolipin remodeling in the heart. J Cardiovasc Pharmacol. 2009;53:290-301.
113. Schlame M, Kelley RI, Feigenbaum A, Towbin JA, Heerdt PM, Schieble T, Wanders RJ, DiMauro S, Blanck TJ. Phospholipid abnormalities in children with Barth syndrome. J Am Coll Cardiol. 2003;42:1994-1999. (Pubitemid 37485578)
114. Schlame M, Ren M. Barth syndrome, a human disorder of cardiolipin metabolism. FEBS Lett. 2006;580:5450-5455. (Pubitemid 44465900)
115. Hauff KD, Hatch GM. Cardiolipin metabolism and Barth syndrome. Prog Lipid Res. 2006;45:91-101. (Pubitemid 43248730)
116. Sparagna GC, Chicco AJ, Murphy RC, Bristow MR, Johnson CA, Rees ML, Maxey ML, McCune SA, Moore RL. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res. 2007; 48:1559-1570. (Pubitemid 47312017)
117. Rosca MG, Vazquez EC, Kerner J, Parland W, Chandler MP, Stanley WC, Sabbah HN, Hoppel CL. Cardiac mitochondria in coronary microembolization-induced heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res. 2008;80:30-39.
118. Shah KB, Duda MK, O'Shea KM, Sparagna GC, Chess DJ, Khairallah RJ, Robillard-Frayne I, Xu W, Murphy RC, Des Rosiers C, Stanley WC. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. Hypertension. 2009;54:605-611.
119. Mohrhauer H, Holman RT. The effect of dose level of essential fatty acids upon fatty acid composition of the rat liver. J Lipid Res. 1963;4: 151-159.
120. Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, Engler MM, Engler MB, Sacks F. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation. 2009;119: 902-907.
121. Valianpour F, Wanders RJ, Overmars H, Vaz FM, Barth PG, van Gennip AH. Linoleic acid supplementation of Barth syndrome fibroblasts restores cardiolipin levels: implications for treatment. J Lipid Res. 2003; 44:560-566. (Pubitemid 37279705)
122. Metcalf RG, James MJ, Gibson RA, Edwards JR, Stubberfield J, Stuklis R, Roberts-Thomson K, Young GD, Cleland LG. Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr. 2007;85:1222-1228. (Pubitemid 46740462)
123. Duda MK, O'Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res. 2009;84:33-41.
124. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei CL. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57:870-879.
125. Gissi-Hf I. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-1230.
126. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a doubleblind, placebo-controlled, 3-arm study. Am Heart J. 2011;161:915-919.
127. Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS. Fish intake and risk of incident heart failure. J Am Coll Cardiol. 2005;45: 2015-2021. (Pubitemid 40814125)
128. Kawabata T, Hirota S, Hirayama T, Adachi N, Hagiwara C, Iwama N, Kamachi K, Araki E, Kawashima H, Kiso Y. Age-related changes of dietary intake and blood eicosapentaenoic acid, docosahexaenoic acid, and arachidonic acid levels in Japanese men and women. Prostaglandins Leukot Essent Fatty Acids. 2011;84:131-137.
129. Chen J, Shearer GC, Chen Q, Healy CL, Beyer AJ, Nareddy VB, Gerdes AM, Harris WS, O'Connell TD, Wang D. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation. 2011;123:584-593.
130. Duda MK, O'Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, Chess DJ, Azimzadeh AM, Harris WS, Sharov VG, Sabbah HN, Stanley WC. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res. 2009; 81:319-327.
131. Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res. 2007;76:303-310. (Pubitemid 350198598)
132. O'Shea KM, Chess DJ, Khairallah RJ, Hecker PA, Lei B, Walsh K, Des Rosiers C, Stanley WC. Omega-3 polyunsaturated fatty acids prevent pressure overload-induced ventricular dilation and decrease in mitochondrial enzymes despite no change in adiponectin. Lipids Health Dis. 2010;9:95.
133. Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. Circulation. 2002;105:2303-2308. (Pubitemid 34535342)
134. McLennan PL, Abeywardena MY, Dallimore JA, Raederstorff D. Dietary fish oil preserves cardiac function in the hypertrophied rat heart. Br J Nutr. 2011 (in press; PMID:22067847).
135. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant. 2006;25:834-838. (Pubitemid 43963369)
136. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83:1505S-1519S. (Pubitemid 44713092)
137. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008;3:279-312. (Pubitemid 351488283)
138. Thies F, Nebe-von-Caron G, Powell JR, Yaqoob P, Newsholme EA, Calder PC. Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged -55 y. Am J Clin Nutr. 2001;73:539-548. (Pubitemid 32176504)
139. Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM, Rifai N, Willett WC, Hu FB. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr. 2004;134:1806-1811. (Pubitemid 38886573)
140. Matsumori A, Sasayama S. The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. Heart Fail Rev. 2001;6:129-136. (Pubitemid 32328175)
141. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res. 1999;85:357-363. (Pubitemid 29398868)
142. Srivastava S, Chandrasekar B, Bhatnagar A, Prabhu SD. Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am J Physiol Heart Circ Physiol. 2002;283: H2612-H2619. (Pubitemid 35345970)
143. Massey KA, Nicolaou A. Lipidomics of polyunsaturated-fatty-acidderived oxygenated metabolites. Biochem Soc Trans. 2011;39: 1240-1246.
144. Blasig IE, Grune T, Schonheit K, Rohde E, Jakstadt M, Haseloff RF, Siems WG. 4-hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am J Physiol. 1995;269: H14-H22.
145. Asselin C, Shi Y, Clement R, Tardif JC, des RC. Higher circulating 4-hydroxynonenal-protein thioether adducts correlate with more severe diastolic dysfunction in spontaneously hypertensive rats. Redox Rep. 2007;12:68-72. (Pubitemid 46210359)
146. Riahi Y, Cohen G, Shamni O, Sasson S. Signaling and cytotoxic functions of 4-hydroxyalkenals. Am J Physiol Endocrinol Metab. 2010; 299:E879-E886.
147. Beresewicz A, Dobrzyn A, Gorski J. Accumulation of specific ceramides in ischemic/reperfused rat heart; effect of ischemic preconditioning. J Physiol Pharmacol. 2002;53:371-382.
148. Dobrzyn A, Knapp M, Gorski J. Effect of acute exercise and training on metabolism of ceramide in the heart muscle of the rat. Acta Physiol Scand. 2004;181:313-319. (Pubitemid 38869743)
149. Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, Ruzickova J, Kopecky J. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia. 2006;49:394-397. (Pubitemid 43185410)
150. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, Kawano H, Yano T, Aoe S, Takeya M, Shimatsu A, Kuzuya H, Kamei Y, Ogawa Y. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol. 2007;27:1918-1925. (Pubitemid 47315642)
151. Moreno-Aliaga MJ, Lorente-Cebrian S, Martinez JA. Regulation of adipokine secretion by n-3 fatty acids. Proc Nutr Soc. 2010;69:324-332.
152. Hajer GR, van der GY, Olijhoek JK, Edlinger M, Visseren FL. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J. 2007;154:750-757.
153. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, Grossman E, Sheps D, Keren G, Roth A. Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006;92:1420-1424. (Pubitemid 44578832)
154. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007;167: 1510-1517. (Pubitemid 47124181)
155. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74:11-18. (Pubitemid 46366942)
156. Oster RT, Tishinsky JM, Yuan Z, Robinson LE. Docosahexaenoic acid increases cellular adiponectin mRNA and secreted adiponectin protein, as well as PPARgamma mRNA, in 3T3-L1 adipocytes. Appl Physiol Nutr Metab. 2010;35:783-789.